Switzerland-based Novartis will pay Xencor $150M up front in the agreement. The two companies will equally share the cost to jointly develop two Xencor antibodies as possible immunosuppressive therapies for cancer, according to a statement on Novartis’ website.
Novartis will additionally have the rights to develop and commercialize four more bispecific antibodies and use Xencor’s antibody technology in up to 10 additional molecules.
Xencor will retain full commercial rights in the U.S., while Novartis will receive commercial rights outside of the U.S.
More articles on supply chain:
Medtronic acquires HeartWare for $1.1B
Leukocyte reduction devices recalled for faulty filters
How Britain’s exit from the EU will affect the drug market
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
